ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

More than 40,000 Cancer Claims Remain Unresolved from Proposed Bayer Monsanto Roundup Weed Killer Lawsuit Settlement

Many cancer victims critical of settlement structure, vow to pursue jury trials

Bayer AG (OTCMKTS:BAYRY)

Bayer shareholders would like to put this significant exposure behind them, however Bayer’s strategy will only ensure that jury trials will take place for years to come.”
— Trial Lawyer Majed Nachawati
DALLAS, TEXAS, UNITED STATES, April 26, 2021 /EINPresswire.com/ -- More than 40,000 current claims on behalf of individuals diagnosed with non-Hodgkins lymphoma after exposure to the Bayer Monsanto Roundup herbicide remain unresolved as criticism mounts that a proposed settlement framework is inconsistent and unfair to cancer victims.

Plaintiffs in multidistrict litigation (MDL) against Roundup maker Bayer AG (OTCMKTS: BAYRY) increasingly see a jury trial as the only avenue for justice, said trial lawyer Majed Nachawati of Dallas-based Fears Nachawati Law Firm.

The Fears Nachawati Law Firm has filed motions on behalf of clients with non-Hodgkins lymphoma seeking to throw out a proposed settlement to the MDL, which would allow Roundup maker Bayer AG to continue selling the glyphosate-based herbicide while shielding it from future cancer lawsuits.

“This proposed settlement has been fatally flawed from the beginning,” Mr. Nachawati said. “Bayer shareholders would like to put this significant exposure behind them, however Bayer’s strategy will only ensure that jury trials will take place for years to come.”

Rather than resolving all the lawsuits together, the proposed settlement allows Bayer’s lawyers to negotiate separately with one law firm at a time. According to published reports, law firms that were part of the MDL leadership committee were among the first to settle and reached agreements that are more than twice the amount the remaining cancer claims are being offered.

Roundup’s active ingredient, glyphosate, has been linked in published reports to the development of non-Hodgkin’s lymphoma and other forms of cancer. Juries in three separate trials heard the evidence and returned multimillion-dollar verdicts against Bayer AG, which acquired Roundup-maker Monsanto in 2018.

The multidistrict litigation (MDL) is In re: Bayer Roundup Products Liability Litigation, case number 3:16-md-02741, in the U.S. District Court for the Northern District of California.

Dallas-based Fears | Nachawati Law Firm represents individuals in mass tort litigation, businesses and governmental entities in contingent litigation and individual victims in complex personal injury litigation. The largest and most diverse products liability law firm in the nation, Fears | Nachawati was ranked No. 1 nationally in product liability filings in federal court over the last three years. For more information, visit https://www.fnlawfirm.com.

John Raggio
Fears Nachawati
2145594630 ext.
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.